Try Calculator
← Back to Compound Library GH SECRETAGOGUES

IGF-1 DES

IGF-1 DES, formally known as des(1-3)IGF-1, is a naturally occurring truncated variant of insulin-like growth factor-1 (IGF-1). The compound is generated through post-translational cleavage that removes the first three amino acids from the N-terminus of the native IGF-1 molecule. Where native IGF-1 contains 70 amino acids, IGF-1 DES retains only 67, yielding a molecular structure that is structurally streamlined but functionally superior in terms of receptor bioavailability. The defining characteristic of IGF-1 DES is its dramatically reduced affinity for IGF binding proteins (IGFBPs). In the human body, IGFBPs bind approximately 98% of all circulating IGF-1, effectively keeping the hormone sequestered and inactive until the body requires it. By removing the glutamate residue at position 3, IGF-1 DES escapes this regulatory checkpoint, making nearly the entirety of administered peptide immediately available to interact with IGF-1 receptors on target cells. This structural difference translates to a compound that is approximately ten times more potent than native IGF-1 at stimulating cell growth and proliferation. Yet despite this enhanced potency, IGF-1 DES is not a synthetic creation. It has been isolated from human brain tissue, bovine colostrum, and porcine uterine tissue, confirming its biological legitimacy as a naturally occurring peptide. The amino acid sequence of IGF-1 DES is: TLCGAELVDA LQFVCGDRGF YFNKPTGYGS SSRRAPQTGI VDECCFRSCD LRRLEMYCAP LKPAKSA IGF-1 DES has a short half-life of approximately 20 to 30 minutes, which distinguishes it from other IGF- 1 variants such as IGF-1 LR3. This brevity makes it well suited for site-specific, localized applications rather than broad systemic effects. The peptide is not approved by the FDA for any medical use and remains classified as a research compound. It is prohibited by the World Anti-Doping Agency (WADA) under the category of Peptide Hormones, Growth Factors, and Related Substances.

How It Works

Receptor Binding and Signaling

IGF-1 DES exerts its biological effects by binding to the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor expressed on nearly every cell in the human body. IGF-1R is composed of two alpha and two beta subunits linked by disulfide bonds. The beta subunits carry intracellular tyrosine kinase domains that become activated upon peptide binding to the extracellular alpha subunits. Upon binding, IGF-1 DES initiates two primary intracellular signaling cascades. The PI3K/Akt/mTOR pathway drives protein synthesis, cell growth, and survival, while the MAPK (Raf/MEK/ERK) pathway promotes cell proliferation, differentiation, and prevention of apoptosis. Together, these pathways create a powerful anabolic and regenerative environment within target tissues.

Reduced IGFBP Binding

Under normal physiological conditions, the six IGF binding proteins (IGFBP-1 through IGFBP-6) bind circulating IGF-1 with affinities equal to or greater than that of the IGF-1 receptor itself. This means the vast majority of endogenous IGF-1 remains bound and inactive at any given time, available only through tightly regulated release mechanisms. IGF-1 DES circumvents this regulatory system. The absence of glutamate at position 3 reduces the peptide’s affinity for IGFBPs to negligible levels. Research has confirmed that IGFBPs from cultured cells, which readily inhibit the biological activities of native IGF-1 and IGF-2, have no significant inhibitory effect on IGF-1 DES. As a result, nearly all administered IGF-1 DES remains free and biologically active, reaching IGF-1 receptors with far greater efficiency than the intact molecule.

Half-Life and Pharmacokinetics

The half-life of IGF-1 DES is approximately 20 to 30 minutes, a sharp contrast to IGF-1 LR3, which carries a half-life of 20 to 30 hours. This rapid clearance is both a limitation and an advantage. It means systemic exposure is minimal and the effects are concentrated around the time and site of injection. When administered intramuscularly, IGF-1 DES acts locally within the injected tissue before being cleared, enabling precise targeting without the prolonged systemic exposure associated with longer-acting IGF-1 variants. The enhanced bioavailability of IGF-1 DES also extends to its insulin-like properties. Research in animal models has demonstrated that IGF-1 DES is two to three times more potent than native IGF-1 at lowering blood glucose, reflecting the greater fraction of active peptide available to promote glucose uptake in peripheral tissues.

Benefits

Enhanced Muscle Hypertrophy

IGF-1 DES stimulates muscle hypertrophy through direct activation of IGF-1 receptors on muscle fibers. Because IGFBP interference is minimal, a far greater proportion of the peptide reaches muscle tissue to trigger protein synthesis via the PI3K/Akt/mTOR pathway. This translates to an enhanced anabolic response compared to native IGF-1 at equivalent doses.

Satellite Cell Activation and Muscle Hyperplasia

One of the most scientifically significant properties of IGF-1 DES is its capacity to activate satellite cells. These are dormant muscle stem cells responsible for muscle fiber repair and regeneration. Most anabolic compounds increase the volume of existing muscle fibers (hypertrophy), but satellite cell activation theoretically allows for the formation of new muscle fibers through hyperplasia. While hyperplasia remains difficult to confirm definitively in humans, the satellite cell-activating potential of IGF-1 DES represents a mechanistically distinct pathway from conventional anabolic agents.

Site-Specific Targeted Effects

The short half-life of IGF-1 DES is particularly valuable for site-specific applications. When injected intramuscularly into a lagging muscle group, the peptide acts locally within that tissue before systemic clearance occurs. This targeted mechanism allows researchers and clinicians to direct the anabolic effect to specific areas without influencing the broader hormonal environment. This is a capability that longer-acting compounds such as IGF-1 LR3 cannot replicate with the same precision.

Tissue Repair and Recovery

IGF-1 plays a foundational role in wound healing and tissue regeneration. IGF-1 DES enhances fibroblast proliferation and collagen synthesis, both of which are critical to repair of muscle, tendon, ligament, and other connective tissues. The enhanced bioavailability of IGF-1 DES means these regenerative effects occur with greater efficiency than those produced by native IGF-1 alone.

Nutrient Partitioning and Glucose Uptake

Like native IGF-1, IGF-1 DES promotes glucose uptake in muscle tissue by enhancing insulin sensitivity and glucose transporter expression. This can improve nutrient partitioning during periods of increased caloric consumption, directing energy substrate preferentially into muscle tissue. The hypoglycemic potency of IGF-1 DES is two to three times greater than that of native IGF-1 in animal models, reflecting the enhanced receptor availability of the free peptide.

Neurological Research Applications

IGF-1 DES has demonstrated considerable promise in neurological research. Studies indicate that it may protect synaptic health, maintain neuron density, and support neuronal survival under conditions of stress or injury. Clinical investigations have explored IGF-1 variants including DES in the context of neurodevelopmental conditions such as Rett syndrome and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The neuroprotective properties of IGF-1 DES likely result from activation of the PI3K/Akt survival pathway in neuronal cells.

Bone Density Support

IGF-1 is essential for both bone formation during development and bone maintenance in adulthood. Higher circulating IGF-1 levels are consistently associated with greater bone mineral density across multiple populations. IGF-1 DES retains the bone-supporting properties of native IGF-1 with enhanced potency, stimulating osteoblast activity and supporting skeletal integrity.

What the Science Shows

Ballard et al. (1987): Discovery of Enhanced Potency Published in Biochemical and Biophysical Research Communications, this foundational study conducted by Ballard and colleagues established the fundamental pharmacological profile of IGF-1 DES. The researchers systematically examined the receptor binding characteristics and biological activities of natural and synthetic IGF-1 variants, including des(1-3)IGF-1. The results demonstrated that IGF-1 DES was approximately ten times more potent than native IGF-1 at stimulating cell hypertrophy and proliferation in cultured cells. The mechanism underpinning this enhanced potency was identified as dramatically reduced affinity for IGF binding proteins. Critically, despite the N- terminal truncation, IGF-1 DES retained full affinity for the IGF-1 receptor, confirming that the structural modification selectively impaired IGFBP binding without compromising receptor engagement.

Ballard et al. (1989): IGFBP Inhibition Study

A follow-up investigation published in the Biochemical Journal explored the inhibitory role of IGF binding proteins on IGF-1 biological activity. The researchers demonstrated that binding proteins derived from cultured cells effectively blocked the growth-promoting activities of both IGF-1 and IGF-2 in a dose- dependent manner. When IGF-1 DES was tested under identical conditions, it was found to be entirely unaffected by these binding proteins. The biological potencies of different IGF-1 forms correlated inversely with their affinity for IGFBPs, providing robust mechanistic confirmation that IGFBP resistance is the primary driver of IGF- 1 DES enhanced activity.

Clark et al. (1990): Growth Effects in Growth Hormone-Deficient Mice Published in the Journal of Endocrinology, this study compared the growth-promoting effects of IGF-1 and IGF-1 DES in growth hormone-deficient (lit/lit) mice, a well-validated model for studying IGF-1 physiology. Researchers administered both compounds at different doses over an extended period and assessed total body growth parameters as well as organ weights. The results demonstrated that 3 micrograms of IGF-1 DES per day produced growth effects equivalent to 30 micrograms of native IGF-1 per day, confirming the approximately ten-fold potency advantage in a living organism. Both total length and nose-rump length increased substantially in IGF-1 DES-treated

animals. Notably, the lower dose of IGF-1 DES also produced measurable increases in kidney and heart weights relative to controls, reflecting broader anabolic activity across multiple organ systems.

Tomas et al. (1997): In Vivo Potency in Large Animal Models Published in the Journal of Endocrinology, this study moved beyond rodent models to test IGF-1 variants with reduced IGFBP affinity in pigs and marmoset monkeys. The objective was to determine whether the enhanced in vitro potency of IGFBP-resistant IGF-1 variants translated to meaningful physiological effects in larger species. The results confirmed that IGF-1 DES was two to three times more potent than native IGF-1 at lowering blood glucose in both species, demonstrating that the enhanced bioavailability conferred by IGFBP resistance translates directly to augmented biological activity in living systems. The investigators also noted anabolic effects on skeletal muscle and neuroprotective properties, supporting the multi-system applicability of IGF-1 DES.

Bailes & Soloviev (2021): IGF-1 Network Overview

Published in Biomolecules (PMC7913862), this comprehensive review from researchers at Royal Holloway University of London provides an authoritative overview of the IGF signaling network, including the roles of IGFBPs, IGFBP-related proteins, and IGF-1 variants including DES. The authors confirm that the six IGFBPs bind approximately 98% of all circulating IGF-1, underscoring the biological significance of IGFBP resistance as a mechanism for enhancing IGF-1 bioavailability. The review also addresses the relevance of IGF-1 monitoring in clinical diagnostics and sports, noting the challenges posed by IGFBP interference in assay sensitivity and the regulatory landscape surrounding IGF- 1 analogues in athletic competition.

Dosing Protocol

Standard Research Protocol

Parameter Specification Notes Dose Range 20 to 100 mcg per injection Titrate from low end Frequency 1 to 2 times daily Training days only Timing Within 10–15 min post-workout IGF-1R expression peaks post-exercise Cycle Length 4 to 6 weeks Prevents receptor downregulation Rest Period 4 to 6 weeks off Allows receptor sensitivity recovery Route Intramuscular or subcutaneous Into or near target muscle

Beginner Protocol

Researchers and practitioners beginning with IGF-1 DES should use a conservative starting dose to assess individual response and tolerance before escalating to standard doses.

Parameter Specification Notes Dose Range 20 to 40 mcg per injection Lower end recommended Frequency Once daily Post-workout only Cycle Length 4 weeks Assess response before extending Route Intramuscular Target muscle group

Site-Specific Protocol

For targeted applications focusing on lagging muscle groups, the dose can be split across multiple injection sites administered pre-workout, allowing local IGF-1 receptor activation during training. Parameter Specification Notes Dose Range 20 to 50 mcg total Split across 2–4 sites Timing 15–30 min pre-workout Prior to training target muscle Sites 2 to 4 injection sites Rotate to reduce tissue irritation Daily Limit 100 mcg maximum Do not exceed regardless of protocol

Draw Volumes by Vial Configuration

Use an insulin syringe marked in units. 100 units equals 1 mL. 1 mg Vial Reconstituted with 1 mL (1,000 mcg/mL) Dose Volume Units on Syringe 20 mcg 0.02 mL 2 units 30 mcg 0.03 mL 3 units 40 mcg 0.04 mL 4 units 50 mcg 0.05 mL 5 units 80 mcg 0.08 mL 8 units 100 mcg 0.10 mL 10 units Vial duration at 50 mcg daily: 20 days

1 mg Vial Reconstituted with 2 mL (500 mcg/mL) Dose Volume Units on Syringe 20 mcg 0.04 mL 4 units 30 mcg 0.06 mL 6 units

40 mcg 0.08 mL 8 units 50 mcg 0.10 mL 10 units 80 mcg 0.16 mL 16 units 100 mcg 0.20 mL 20 units Vial duration at 50 mcg daily: 20 days

Reconstitution Instructions

IGF-1 DES is more structurally delicate than many research peptides. Particular care must be taken during reconstitution to preserve peptide integrity. 1. Gather materials: lyophilized peptide vial, bacteriostatic water, sterile reconstitution syringe, and alcohol swabs. 2. Wipe both the peptide vial stopper and bacteriostatic water vial with fresh alcohol swabs. Allow to air dry. 3. Draw 1 to 2 mL of bacteriostatic water into the sterile syringe. 4. Insert the needle through the rubber stopper at an angle and direct the water stream to trickle slowly down the inside wall of the vial. Do not inject directly onto the lyophilized powder. 5. Gently swirl the vial (do not shake) until the powder is completely dissolved. The solution should be clear and colorless. 6. If the solution appears cloudy, discolored, or contains visible particles, discard and do not use.

Side Effects

Common Side Effects

IGF-1 DES. Because the peptide promotes glucose uptake in peripheral tissues at two to three times the efficiency of native IGF-1, blood glucose can drop rapidly following injection. Symptoms include shakiness, diaphoresis, lightheadedness, confusion, and in severe cases, loss of consciousness. Fast-acting carbohydrates such as glucose tablets, juice, or candy must be available at all times during administration.

particularly with repeated administration to the same location. Rotating injection sites is essential to minimize these effects.

resolves as the body adjusts to the peptide.

Hormonal Effects

hypothalamic-pituitary-gonadal axis, distinguishing it mechanistically from anabolic-androgenic steroids.

signaling pathways via IGF-1R cross-reactivity with the insulin receptor.

negative feedback loop associated with exogenous growth hormone.

Rare and Theoretical Side Effects

pathways influence fluid balance.

rapid tissue changes.

injection sites. No confirmed cases have been documented in the peer-reviewed literature at research doses.

Long-Term Considerations and Oncological Risk

IGF-1 is a well-established mitogen, promoting cell division across multiple tissue types. While no peer- reviewed studies have demonstrated cancer causation from IGF-1 peptide administration at research doses, the theoretical concern is scientifically grounded. Elevated endogenous IGF-1 levels have been associated with increased incidence of certain cancers in epidemiological studies. Individuals with any history of cancer, precancerous lesions, or conditions associated with uncontrolled cell proliferation should not use IGF-1 DES or any IGF-1 analogue.

Contraindications and Precautions

Absolute Contraindications

Relative Contraindications and Cautions

Combined use with insulin or oral hypoglycemics significantly increases hypoglycemia risk.

conditions requires careful consideration and medical supervision.

Drug Interactions

must be monitored closely if both compounds are administered.

blood glucose-lowering effects of IGF-1 DES.

amplify both anabolic and adverse effects.

Special Populations

glucose homeostasis in aging populations.

IGF-1 DES vs. IGF-1 LR3: A Direct Comparison

IGF-1 DES and IGF-1 LR3 are the two most widely studied IGF-1 analogues in research settings. While both are derived from native IGF-1 and share the same receptor target, they differ substantially in structure, pharmacokinetics, and optimal application. Characteristic IGF-1 DES IGF-1 LR3 Amino Acids 67 (N-terminal truncation) 83 (C-terminal extension) Potency vs. Native IGF-1 ~10x more potent ~3x more potent Half-Life 20–30 minutes 20–30 hours IGFBP Affinity Very low (near-zero) Greatly reduced Effect Type Localized, site-specific Systemic, prolonged Best Application Targeted muscle groups, injury Overall anabolic support sites Hypoglycemia Risk Higher (2–3x native IGF-1) Moderate Injection Timing Post-workout or site-specific Post-workout or daily pre-workout

The most important practical distinction is that IGF-1 DES is optimal for targeted, localized applications where precision matters, while IGF-1 LR3 is better suited for researchers seeking sustained, systemic IGF- 1 pathway activation. The two compounds may be used in complementary protocols: GH secretagogues such as CJC-1295 and Ipamorelin can elevate systemic GH and IGF-1, while concurrent IGF-1 DES provides localized augmentation at specific target tissues.

Success Tips

Time Injections Strategically

The 20 to 30 minute half-life of IGF-1 DES makes timing the most critical variable in any protocol. For general anabolic applications, injection immediately post-workout capitalizes on the peak window of IGF- 1 receptor expression in trained muscle. For site-specific targeting, injection 15 to 30 minutes before training the target muscle allows peak receptor exposure to coincide with mechanical activation.

Prioritize Peri-Workout Nutrition

IGF-1 DES substantially enhances nutrient uptake in muscle tissue. Consuming a combination of fast- digesting protein and carbohydrates around injection time creates an optimal anabolic environment. This nutritional support also helps buffer against hypoglycemia risk.

Begin With the Lowest Effective Dose

Individual sensitivity to IGF-1 DES varies considerably. Starting at 20 to 40 mcg allows assessment of glucose response and local tissue reaction before progressing to standard doses. Rushing to higher doses before establishing individual tolerance increases hypoglycemia risk without providing proportional benefit.

Monitor Blood Glucose Consistently

Keep fast-acting carbohydrates readily accessible during and after every administration session. Learn to recognize early signs of hypoglycemia, including light-headedness, shakiness, and sweating. Consider using a glucometer to track glucose response, particularly when initiating a new protocol or increasing dose.

Respect Cycle Structure

Continuous use of IGF-1 DES leads to receptor desensitization and downregulation, diminishing returns over time. A cycle structure of 4 to 6 weeks on followed by an equal period off maintains receptor sensitivity and preserves long-term response to the peptide.

Use Purposefully and Specifically

IGF-1 DES is most valuable when applied to a specific objective: bringing up a lagging muscle group, accelerating recovery from a localized injury, or enhancing tissue regeneration in a targeted area. It is less efficient than IGF-1 LR3 for broad systemic anabolic applications due to its rapid clearance.

Storage and Handling

Before Reconstitution (Lyophilized Powder)

agitation.

After Reconstitution (Liquid Solution)

matter.

Legal Status

United States

IGF-1 DES is not approved by the U.S. Food and Drug Administration for any human medical use. It is legally available as a research chemical for purchase and use in laboratory research contexts. It is not legal to sell for human consumption or to market with therapeutic claims.

World Anti-Doping Agency (WADA) IGF-1 DES is prohibited at all times under the WADA Prohibited List, Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Any athlete subject to anti-doping oversight should not use IGF-1 DES or any IGF-1 analogue. All forms of IGF-1 and its analogues are banned substances regardless of method of administration.

Frequently Asked Questions

Q: How does IGF-1 DES differ from IGF-1 LR3?

IGF-1 DES is a 67-amino acid N-terminal truncation of native IGF-1, while IGF-1 LR3 is an 83-amino acid C-terminal extension. DES is approximately ten times more potent than native IGF-1 with a half-life of 20 to 30 minutes, making it ideal for site-specific applications. LR3 is approximately three times more potent with a half-life of 20 to 30 hours, providing sustained systemic effects. The choice between them depends entirely on the intended research objective. Q: Can IGF-1 DES be administered daily? Most research protocols restrict administration to training days only. The short half-life means no meaningful accumulation occurs between injections. Using the compound only on training days aligns the anabolic stimulus with the exercise-induced increase in IGF-1 receptor expression. Q: What is the hypoglycemia risk with IGF-1 DES? Hypoglycemia is a real and primary concern. IGF-1 DES promotes peripheral glucose uptake at two to three times the potency of native IGF-1. Adequate carbohydrate intake around injection times, access to fast-acting glucose sources, and awareness of early hypoglycemia symptoms are essential safety measures.

Q: Does IGF-1 DES require post-cycle therapy (PCT)?

No. IGF-1 DES does not suppress endogenous testosterone production or interfere with the hypothalamic- pituitary-gonadal axis. PCT is not necessary when IGF-1 DES is used as a standalone compound. If it is co-administered with anabolic steroids or other suppressive agents, PCT requirements are determined by those compounds, not by IGF-1 DES. Q: How quickly can results be expected? Effects on recovery and nutrient partitioning may be perceptible within the first week of use. Measurable changes in muscle composition and performance parameters typically require three to four weeks of consistent administration paired with appropriate training and nutrition. Q: Can multiple muscles be targeted in a single session? Yes. The dose can be divided across two to four injection sites when targeting multiple muscle groups simultaneously. The total daily dose should not exceed 100 mcg regardless of how it is distributed. Q: Is IGF-1 DES safe for long-term continuous use? Long-term safety data in humans is limited. The available evidence and theoretical considerations support cycling: four to six weeks of use followed by an equivalent rest period. Continuous use is not recommended due to receptor downregulation risk and the unresolved question of long-term mitogenic exposure. Q: What are the key differences between IGF-1 DES and native IGF-1? The primary differences are structural (67 vs. 70 amino acids), pharmacological (minimal IGFBP binding vs. approximately 98% circulating protein binding), and practical (ten-fold greater potency, 20 to 30 minute half-life vs. minutes for free native IGF-1 in plasma). These differences make IGF-1 DES a fundamentally different tool for targeted, short-duration receptor activation.

References

7. Ballard FJ, Francis GL, Ross M, et al. Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. Biochem Biophys Res Commun. 1987;149(2):398–404. 8. Ross M, Francis GL, Szabo L, et al. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989;258(1):267– 272. 9. Clark RG, Jansson JO, Isaksson O, Robinson IC. Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J Endocrinol. 1985;104(1):53–61. 10. Tomas FM, Walton PE, Dunshea FR, Ballard FJ. IGF-I variants which bind poorly to IGF- binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys. J Endocrinol. 1997;155(2):377–386. 11. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213–223. 12. Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9(9):1970. 13. Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021;11(2):217. doi:10.3390/biom11020217. PMC7913862. 14. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53–74. 15. Philippou A, Papageorgiou E, Bogdanis G, et al. Expression of IGF-1 isoforms after exercise- induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo. 2009;23(4):567–575. 16. Ballard FJ, Ross M, Upton FM, Francis GL. Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively. Biochem J. 1988;249(3):721–726.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch